Depression - Articles - Page 16

l-Methylfolate for Depression: Costly Mistake or Good Thinking?

August 1, 2019

Folic acid and l-methylfolate are two versions of the same vitamin. Both are popular for antidepressant augmentation, but one is a expensive prescription. We compared them side-by-side and found that one has a slight advantage.

A New Treatment for Bipolar Depression

August 1, 2019

With Vrylar’s new approval, there are now four atypicals antipsychotics with an indication in bipolar depression. Only two of these, however, are known to work in mania as well as depression. None of the atypicals stands out as the perfect choice for bipolar depression, but there are pros and cons to each that make them fitter better with certain patients.

The Carlat Report Goes to APA Part II

July 29, 2019

More highlights from the American Psychiatric Association's 2019 meeting in the final installment of this two-part series. Expert interviews with Manpreet Singh on childhood mood disorders and Nikhil Rao on novel medications for sleep. Learn what to do when children get worse on antidepressants, and how to use clonidine...

Editor's Choice: An Antidepressant Diet Expert Q&A

July 11, 2019

Chris Aiken, MD

I was a reader of The Carlat Psychiatry Report before I was an editor, and there were two things that led me to subscribe to it:1) They cover topics that get missed in the psychiatric press, like practical tips and treatments that aren't backed by a promotional budget.2) They give...

Esketamine Gets FDA Approval

July 3, 2019

Michael Posternak, MD. Psychiatrist in private practice, Boston, MA. Dr. Posternak has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

On March 5, 2019, the FDA approved esketamine (Spravato) nasal spray as add-on therapy to traditional antidepressant medications for treatment-resistant depression (TRD). In this article, I will describe the events that led to esketamine’s development, review the data submitted to the FDA, and discuss what the future might hold for esketamine.

Risk Evaluation and Mitigation Strategy (REMS) Programs

July 3, 2019

Certain psychiatric treatments require both the healthcare provider and patient to enroll in a Risk Evaluation and Mitigation Strategy (REMS) program before they are administered. Here are links to enroll.

Brexanolone (Zulresso) for Postpartum Depression

July 3, 2019

Talia Puzantian, Chris Aiken, MD, and Chris Aiken

Talia Puzantian, PharmD, BCPP Chris Aiken, MD Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Every week of depression takes a toll on infant development, so this rapid-acting treatment fills a unique need. Here we review the clinical data and the pragmatics of getting patients connected with the therapy.

Lithium in Geriatric Depression

July 3, 2019

Jason Mallo, DO

Jason Mallo, DO Dr. Mallo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Lithium is underutilized in geriatric depression, but this study suggests it may have unique benefits there.

How to Use Amantadine

June 24, 2019

Rarely used but often studied, amantadine is a medicine that doesn't fit neatly into any boxes. It's thought to work in OCD, autism, depression, cognition, ADHD, weight loss, sexual dysfunction, and traumatic brain injury. But how good is that research, and when should you use it? Chris Aiken and Kellie...

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019

With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.